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Abstract: Alzheimer’s disease is known to be the most common form of dementia in the elderly. It is clinically characterized by impair-
ment of cognitive functions, as well as changes in personality, behavioral disturbances and an impaired ability to perform activities 
of daily living. To date, there are no effective ways to cure or reverse the disease. Genetic studies of early-onset familial Alzheimer’s 
disease cases revealed causative mutations in the genes encoding β-amyloid precursor protein and the γ-secretase-complex components 
presenilin-1 and presenilin-2, supporting an important role of β-amyloid in the pathogenesis of Alzheimer’s disease. Compromised 
function of the choroid plexus and defective cerebrospinal fluid production and turnover, with diminished clearance of β-amyloid, may 
play an important role in late-onset forms of Alzheimer’s disease. If reduced cerebrospinal fluid turnover is a risk factor for Alzheimer’s 
disease, then therapeutic strategies to improve cerebrospinal fluid flow are reasonable. However, the role of deficient cerebrospinal fluid 
dynamics in Alzheimer’s disease and the relevance of choroidal proteins as potential therapeutic targets to enhance cerebrospinal fluid 
turnover have received relatively little research attention. In this paper, we discuss several choroidal proteins, such as Na+-K+ ATPase, 
carbonic anhydrase, and aquaporin 1, that may be targets for pharmacological up-regulation of cerebrospinal fluid formation. The search 
for potentially beneficial drugs useful to ameliorate Alzheimer’s disease by facilitating cerebrospinal fluid production and turnover may 
be an important area for future research. However, the ultimate utility of such modulators in the management of Alzheimer’s disease 
remains to be determined. Here, we hypothesize that caffeine, the most commonly used psychoactive drug in the world, may be an 
attractive therapeutic candidate for treatment of Alzheimer’s disease since long-term caffeine consumption may augment cerebrospinal 
fluid production. Other potential mechanisms of cognitive protection by caffeine have been suggested by recent studies.
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Introduction
Alzheimer’s disease (AD), the most common type of 
dementia among older people, is a progressive neu-
rodegenerative disorder characterized clinically by a 
gradual decline in cognition and daily functioning and 
behavioural alterations.1 Principal neuropathological 
hallmarks of AD include extracellular senile plaques 
containing β-amyloid (Aβ) derived from β-amyloid 
precursor protein (APP) after sequential cleavage by 
β-secretase and γ-secretase, and intracellular neurofi-
brillary tangles caused by abnormally phosphorylated 
tau protein.1 Despite major advances in understanding 
the molecular etiology of the disease, progress in the 
clinical treatment of AD patients has been extremely 
limited. Therefore, new and more effective therapeu-
tic approaches are needed. Early-onset familial AD 
caused by mutations in the genes encoding APP and 
the  γ-secretase-complex  components  presenilin-1 
and presenilin-2 accounts for less than 5% of the total 
number of AD cases.2 The discovery of pathogenic 
mutations in these three genes in rare patients with 
autosomal dominant, early-onset AD provided incon-
testable evidence that aberrant APP processing can 
be sufficient to trigger the pathological cascade lead-
ing to AD.3 The pathological accumulation of Aβ in 
the far more common late-onset AD is more likely 
to be the result of defects in the clearance of Aβ.3 
There  is  evidence  that  production  and  turnover  of 
cerebrospinal  fluid  (CSF)  help  to  clear  toxic  mol-
ecules such as Aβ from the interstitial-fluid space of 
the brain to the bloodstream.4 Reduced formation of 
CSF, with diminished clearance of β-amyloid, is sus-
pected to be a contributor to the pathogenesis of AD.4 
  Consequently, pharmacological targeting of choroi-
dal proteins involved in CSF production may provide 
a new therapeutic approach for AD since such modu-
lators may improve the CSF turnover and clearance 
of potentially toxic metabolites, such as Aβ, from the 
brain. However, the role of deficient CSF dynamics in 
AD and the relevance of choroidal proteins as poten-
tial therapeutic targets to enhance CSF turnover have 
received  relatively  little  research  attention.  In  this 
paper, we discuss several choroidal proteins that may 
be targets for pharmacological up-regulation of CSF 
formation, and hypothesize that caffeine may be an 
attractive therapeutic candidate for treatment of AD 
since long-term caffeine consumption may augment 
CSF production.
Abnormal csF Flow  
may be Linked to AD
CSF production and turnover have been shown to be 
decreased  in  aging  and  in  pathological  conditions, 
such as normal pressure hydrocephalus (NPH) and 
AD.4 In NPH, there is evidence for CSF stagnation 
with decreased clearance of various   macromolecules.5 
Although the primary change in NPH is an increase 
in CSF outflow resistance, decreased CSF production 
also has been reported.4–6 Both conditions lead to a 
decrease in CSF turnover and, in turn, a decreased 
clearance of macromolecules.5 In NPH, a decrease in 
clearance of Aβ and tau is suggested by the higher 
than expected coincidence of AD pathology in corti-
cal biopsy samples obtained at shunt   implantation.5 
The  coincidence  of  AD  neuropathology  among 
patients with NPH varies from 25%–75% depend-
ing  upon  the  severity  of  the  clinical    dementia.7 
As  noted  above,  a  decrease  in  CSF  production  is 
also found in AD.8 Using the Masserman technique, 
  Silverberg et al8 measured a 50% decrease in CSF 
production among AD patients when compared with 
  Parkinson’s disease controls. Mean CSF production 
in AD was 0.20 ± 0.06 ml/min, and in controls was 
0.42 ± 0.13 ml/min.4 The authors calculated a three-
fold decrease in CSF turnover in AD.4 Age-associated 
reduction in CSF production, with diminished clear-
ance of Aβ, may be a key factor in the onset and pro-
gression of AD,4 and may be a particularly important 
mechanism of amyloid toxicity in late-onset AD cases 
in whom overproduction of Aβ may not be operative. 
Higher concentrations of Aβ increase the probability 
of aggregation and fibril formation.4,9 Hence, reduced 
CSF clearance of Aβ should facilitate amyloid burden 
in the brain.4 In   contrast to the 40-amino acid form 
of Aβ, the longer 42-residue form is more prone to 
aggregate and form plaques.4
Data on the relationship between AD and cere-
brospinal fluid pressure (CSFP) are rather scarce in 
the literature. Intracranial pressure (ICP) depends on 
cerebral tissue volume, cerebrospinal fluid volume 
and cerebral blood volume. Interestingly,   Silverberg 
et al7 reported in 2006 on intraventricular CSFP in 
patients with AD. Seven of the 181 subjects (3.9%) 
with no clinical or radiographic signs of NPH had an 
opening CSFP .200 mmH2O.7 For this AD-elevated 
CSFP group, the mean CSFP was 249 ± 20 mmH2O. 
As the authors hypothesised previously, in the   setting Cerebrospinal fluid production and Alzheimer’s disease
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of pre-existing AD, NPH could arise with an increase 
in CSF outflow resistance due to amyloid deposi-
tion  and  fibrosis  in  the  meninges  and  arachnoid 
  granulations.7 In an animal model of NPH, CSFP 
is initially elevated but soon returns to normal after 
ventricular enlargement, decreased CSF production 
and other compensatory events.7,10 Silverberg et al7 
anticipated that the AD patients in their study with 
elevated  CSFP  were  in  the  earliest  stages  of  this 
process  at  the  time  that  their  elevated  pressures 
were discovered, and that over time they would go 
on to develop enlarged ventricles and clinical signs 
of NPH. The AD group without elevated CSFP con-
sisted of 174 subjects (the remaining 96.1%). Mean 
opening CSFP in this group was 103 ± 47 mm H2O, 
which  was  statistically  significantly  lower  when 
compared  to  the AD-elevated  CSFP  group  and  a 
somewhat younger non-demented control group of 
subjects  with  Parkinson’s  disease  (140  ±  60  mm 
H2O).6,7 Forty-two of the 174 subjects (24.1%) had a 
CSFP lower than the normal range.11 This is a much 
higher proportion than one would expect from a nor-
mal population. An unexpected finding of this study 
was the relatively high (.30%) proportion of sub-
jects with moderate to severe dementia as measured 
by Mattis Dementia Rating Scale total scores below 
100,  despite    inclusion-exclusion  criteria  designed 
to capture subjects with mild to moderate demen-
tia (Mini-Mental State Examination score between 
15 and 24, inclusive).7,12 Although not specifically 
investigated in this study, cerebral atrophy associated 
with moderate to severe AD could be hypothesised 
to be associated with lower CSFP.11 Theoretically, 
the marked reduction in CSF production observed 
in AD patients might lead to a further reduction of 
the CSFP.
There  is  some  scientific  rationale  for  consider-
ing AD, at least in part, to be a choroid plexus (CP) 
disease, in that reduced CSF production and turnover 
may contribute to the difficulty in clearing Aβ from 
the aging brain.13 CSF is produced mainly by the four 
choroid plexuses that are found one in each ventricle 
of the brain.1,4,13–16 The CPs are highly vascularized 
villous structures covered by a single layer of epithe-
lial cells.15,16 CPs have multiple functions of synthesis, 
secretion, active transport and selective reabsorption 
of  deleterious  substances.15  In  young  adults,  CSF 
is  completely  renewed  six  times  a  day.13  Choroid 
epithelial cells synthesize numerous crucial molecules, 
such as transthyretin, which sequesters the β-amyloid 
protein  and  inhibits  fibrillotransformation.13,16  The 
levels of transthyretin have been reported to be low-
ered in the CSF of AD patients.15 Structural changes 
in the CP coincide with diminished CSF production 
in ageing, AD, and NPH.4 In AD, choroid plexuses 
present  similar,  although  much  more  pronounced, 
abnormalities  than  those  observed  in  ageing.15,16 
The CP in AD shows epithelial atrophy, basement 
membrane thickening, cyst formation, lipid accumu-
lation,  fibrosis,  calcification,  and  hyalinisation  and 
amyloid deposition in choroidal blood vessels.4
Mechanisms of csF Formation
A review by Brown et al14 highlighted the molecular 
mechanisms of CSF production. The epithelial cells 
of the CP secrete CSF, by a process that involves the 
transport of Na+, Cl- and HCO3
- from the blood to the 
ventricles of the brain.14 This creates an osmotic gra-
dient that is accompanied by the secretion of H2O.14 
The movement of ions across the cellular membrane 
is  mediated  by  specific  transporters  and  ion  chan-
nels that are distributed unequally on the basolateral 
and apical sides of the CP epithelial layer.14 Na+-K+ 
ATPase, K+ channels and Na+-K+-2Cl- cotransporters 
are expressed in the apical membrane.14 By contrast the 
basolateral membrane contains Cl--HCO3
- exchangers, 
a variety of Na+-coupled HCO3
- transporters and K+-Cl- 
cotransporters.14 Aquaporin 1 (AQP1) mediates water 
transport at the apical membrane, but the route across 
the basolateral membrane is unknown.14
Although  stasis  of  CSF  may  be  a  factor  in  the 
etiology of AD, potential pharmacological strategies 
to improve CSF flow have received little research 
attention. Possible approaches to modify CSF forma-
tion were elaborated in a review by Johanson et al.17 
  However, this field remains largely unexplored in AD. 
In the present paper, we discuss several possible targets 
in choroid plexus for pharmacologically augmenting 
the rate of CSF formation, thereby enhancing CSF 
turnover that is severely compromised in AD. It is not 
the purpose of this review to be exhaustive or to dis-
cuss all the potential sites for drug actions to accelerate 
CSF production. Theoretically, transcription factors 
in the nucleus, enzymes in the cytoplasm, and trans-
porters/channels and receptors at the limiting plasma 
membrane are all potential drug targets.17 Instead, the Wostyn et al
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present review will summarize some   relevant data in 
support of its main view.
choroidal proteins Involved In csF  
production as potential Drug Targets  
for AD Therapy
Among the numerous proteins involved in choroidal 
CSF production, it is known that Na+-K+ ATPase, 
carbonic  anhydrase  II  (CA  II), AQP1,  and  solute 
carrier  family  4,  sodium  bicarbonate  transporter, 
member  10  (SLC4A10)  are  major  contributors  to 
CSF secretion.18,19 The Na+-K+ ATPase is a ubiqui-
tous protein which catalyses 1 molecule of ATP to 
exchange 3 Na+ ions for 2 K+ ions across the cell 
membrane.20  In  the  choroid  plexus,  this  enzyme 
is located in the luminal surface and provides the 
driving force for CSF production.18 Inhibitors of the 
Na+-K+ ATPase pump, eg, the cardiac glycoside oua-
bain, have been shown to reduce CSF production, 
and the movement of Na+ into the CSF.17 A recent 
study in rats showed that the long-term consump-
tion of caffeine, the most commonly used psychoac-
tive drug in the world and non-selective adenosine 
A1 and A2A receptor antagonist, increased CSF pro-
duction, associated with the increased expression of 
Na+-K+ ATPase and increased cerebral blood flow.18 
By contrast, acute treatment with caffeine decreased 
the  production  of  CSF,  suggesting  ‘effect  inver-
sion’ associated with caffeine, which was mediated 
by increased expression of the A1 adenosine recep-
tor, in the choroid plexus of rats chronically treated 
with caffeine.18 In accordance with previous results 
showing increased expression of Na+-K+ ATPase in 
A1 adenosine receptor transgenic mice, this study 
showed that the A1 adenosine receptor regulates the 
expression of Na+-K+ ATPase in the choroid   plexus.18 
Because caffeine is commonly ingested chronically, 
it is important to note that long-term exposure to 
adenosine receptor antagonists like caffeine can have 
effects that resemble the acute effects of adenosine 
receptor agonists, due likely to up-regulation of ade-
nosine receptors (A1 and A2A) and adaptive changes 
leading  to  adenosine  receptor    sensitization.21  Of 
major interest for the view presented here, recent 
epidemiological  and  experimental  studies  suggest 
that long-term caffeine consumption may be pro-
tective against AD.21–23   Epidemiologically, a retro-
spective study showed that the incidence of AD was 
inversely    associated with the caffeine intake during 
the 20 years that preceded diagnosis of AD.23 Since 
increased  CSF  production  may  improve  the  CSF 
turnover and clearance of potentially toxic metabo-
lites, such as Aβ, it seems reasonable to speculate 
that  long-term  caffeine  consumption  could  exert 
protective  effects  against AD,  at  least  in  part  by 
facilitating CSF   secretion. To the best of our knowl-
edge,  no  previous  study  has  suggested  increased 
CSF production as a possible mechanism underlying 
the inverse association between caffeine consump-
tion and AD. However, there could be other poten-
tial mechanisms of cognitive protection by caffeine. 
Among  them,  the  antioxidant  properties  of  caf-
feine, its   anti-inflammatory capacities, its ability to 
block disruptions of the blood-brain barrier, and its 
  well-documented blockade of adenosine A1 and A2A 
receptors have been proposed to underlie its ability 
to protect against AD.22,24 Furthermore, in a recent 
study, Arendash et al22 reported that long-term caf-
feine administration that began in young adulthood 
protected AD transgenic mice against otherwise cer-
tain cognitive impairment in older age, while also 
limiting their brain production of Aβ due to reduced 
expression of both β-secretase and presenilin-1/γ-
secretase. The ability of caffeine to reduce Aβ pro-
duction was confirmed in neuronal cell cultures from 
these same transgenic mice, wherein concentration-
dependent  decreases  in  both  Aβ  (1–40)  and  Aβ 
(1–42) were observed.22 In another study, Arendash 
et  al25  found  that  aged,  cognitively-impaired  AD 
transgenic mice given a moderate amount of daily 
caffeine exhibited a restoration of working memory 
to the level of normal, aged mice. In these same aged 
AD mice, which had pre-existing and substantial Aβ 
burden, caffeine treatment reduced both soluble and 
deposited (insoluble) brain Aβ levels.25 Cao et al24 
recently reported that acute caffeine administration 
to both young adult and aged AD transgenic mice 
rapidly reduced Aβ levels in both brain interstitial-
fluid and plasma without affecting Aβ elimination. 
A single treatment with caffeine did not affect the 
half-life of interstitial-fluid Aβ, demonstrating that 
caffeine had affected brain Aβ production rather than 
its   elimination.24 The latter, however, is not inconsis-
tent with the idea that long-term caffeine consump-
tion may exert protective effects against AD at least 
in part by increasing CSF production and clearance. Cerebrospinal fluid production and Alzheimer’s disease
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Indeed, chronic but not acute treatment of rats with 
caffeine increased CSF production.18
Carbonic  anhydrase,  a  zinc-containing  enzyme, 
is present in many tissues of the body, including the 
brain,  and  catalyzes  the  interconversion  between 
CO2 and HCO3
-.26 There are at least seven isozymes 
of carbonic anhydrase in humans.26 The most active 
is isozyme II.26 In addition to its involvement in pH 
regulation, HCO3
- reabsorption and CO2 expiration, 
CA plays a crucial role in signal processing, long-
term synaptic transformation and attentional gating 
of memory storage.27 Carbonic anhydrases also play 
an important role in CSF production.14,18 The main 
evidence for this is that acetazolamide, a CA inhibi-
tor, reduces CSF secretion in rats by as much as 50%, 
and that acetazolamide can also reduce CSF pressure 
in  children  with  hydrocephalus.14  CA  dysfunction 
impairs cognition and is associated with mental retar-
dation, Alzheimer’s disease and aging.27 A previous 
study  reported  significantly  lower  enzyme  activity 
of carbonic anhydrase in AD autopsy homogenates 
of  the  temporal  lobe  compared  with  age-matched 
controls, a fact strongly supporting the involvement 
of  CAs  in  cognitive  dysfunctions  characteristic  of 
this  disease.28,29  Moreover,  a  study  by  Masseguin 
et al30 showed that aging affects choroidal proteins 
involved in CSF production. The authors compared 
choroid  plexuses  of  Sprague-Dawley  rats  aged  10 
or  20  months  with  those  of  3-month-old  ones.30 
  Progressive and age-related changes in the Na+-K+ 
ATPase, carbonic anhydrase II and AQP1 expressions 
at the apical and/or cytoplasmic level, as suggested 
by both the decreases in the intensities of immunocy-
tochemical and in situ hybridization signals, indicated 
that aging decreases notably the protein expression of 
the enzymes and transporters known to regulate the 
CSF production in choroid plexus.30 A previous study 
reported  that  phenylalanine,  a  carbonic  anhydrase 
activator, when administered to experimental animals 
produces a relevant pharmacological enhancement of 
synaptic efficacy, spatial learning and memory, due 
to the rapid and efficient increase of bicarbonate con-
centration in memory-related neural structures.29,31,32 
This class of enzyme modulators might thus be useful 
for the treatment of AD, aging and other conditions in 
which spatial learning and memory therapy need to be 
enhanced.29,31 Interestingly, the well known selective 
serotonin  reuptake  inhibitors  fluoxetine,    sertraline 
and citalopram were shown to be very effective in 
patients with AD who also have major depression.29 
Casini et al29 reported the potent activatory proper-
ties of these three pharmacological agents against the 
most widespread isozymes, CA I and CA II, both of 
which are associated with critical physiological func-
tions  in  a  multitude  of  tissue. This  suggested  that 
the  efficacy  of  these  three  pharmacological  agents 
in patients with AD who also have major depression 
might be due, at least in part, to their CA activating 
properties.29 Given that CAs also play an important 
role in CSF production, here, we raise the question of 
whether CA activators could also ameliorate AD by 
facilitating CSF production, turnover and clearance. 
However, we are not aware of studies which have 
investigated this hypothesis.
Other  proteins  including  AQP1  and  SLC4A10 
are  also  major  contributors  to  CSF  production.18,19 
SLC4A10  is  present  in  multiple  tissues  and  is 
expressed  in  the  basolateral  membrane  of  the  CP 
epithelium.14,33 This transporter mediates the efflux 
of one Cl- in exchange for the influx of one Na+ and 
two  HCO3
-.14 Targeted  mutations,  such  as  an  exon 
deletion in SLC4A10 knockout mice, resulted in an 
88% reduction in brain ventricle size from decreased 
CSF production as compared to wild-type mice.19,34 
The  AQP1  water  channel  mediates  water  move-
ment across membranes in the brain, kidney, vascu-
lar system, and other tissues.35 AQP1 is abundant in 
the choroid plexus and is likely to have a major role 
in mediating water transport across the apical mem-
brane during CSF secretion.14,35 AQP1 knockout mice 
showed reduced CSF production and ICP compared 
with wild-type mice.36 As noted above, aged Sprague-
Dawley rats have substantially less AQP1 expression 
in choroid plexus epithelium than do young ones.30 
As noted earlier, with age, CSF production decreases 
and could increase the risk for development of late-
onset AD.4 Recently, Johanson et al17 suggested the 
possibility of therapeutically up-regulating or restor-
ing AQP1 expression in aged humans when the CSF 
turnover rate is compromised by AD. Given the possi-
ble role for AQP1 in the progressive functional decline 
of CP in aging, and its hypothetical relationship to an 
increased risk of AD, AQP1 could be a potential drug 
target for novel therapy of AD.37 Agonists of AQP1 
could augment CSF production, enhancing the rate of 
CSF turnover.Wostyn et al
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Considering  the  above,  it  seems  reasonable  to 
speculate that pharmacological targeting of choroidal 
proteins essential for CSF production may provide 
a new therapeutic approach for Alzheimer’s disease 
since such modulators may improve the CSF turn-
over and clearance of potentially toxic metabolites, 
such as β-amyloid, from the brain. Hence, choroidal 
proteins involved in CSF secretion may be promis-
ing pharmacological targets for Alzheimer’s disease 
therapy.
conclusions
Compromised  function  of  the  choroid  plexus  and 
defective CSF production and turnover, with dimin-
ished clearance of Aβ, may play an important role 
in late-onset forms of AD. If reduced CSF turnover 
is a risk factor for AD, then therapeutic strategies to 
improve CSF flow are reasonable. However, the role 
of deficient CSF dynamics in AD and the relevance of 
choroidal proteins as potential therapeutic targets to 
enhance CSF turnover have received relatively little 
research attention. In this paper, we discussed several 
choroidal proteins, such as Na+-K+ ATPase, carbonic 
anhydrase, and AQP1, that may be targets for pharma-
cological up-regulation of CSF formation. The search 
for potentially beneficial drugs useful to ameliorate 
AD by facilitating CSF production and turnover may 
be an important area for future research. However, 
the ultimate utility of such modulators in the man-
agement of AD remains to be determined. Here, we 
hypothesized that caffeine, the most commonly used 
psychoactive  drug  in  the  world,  may  be  an  attrac-
tive therapeutic candidate for treatment of AD since 
long-term caffeine consumption may augment CSF 
production. Other potential mechanisms of cognitive 
protection by caffeine have been suggested by recent 
studies.
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